Imiquimod in the Treatment of Cutaneous Warts: An Evidence-Based Review

American Journal of Clinical Dermatology

Volumn 15, Issue 5, 2014, Pages 387-399

  Ahn, Christine S ^a   Huang, William W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ADULT; ANTIVIRAL THERAPY; CHILD; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CUTANEOUS WART; DISEASE CLEARANCE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EROSION; ERYTHEMA; HUMAN; IMMUNE STATUS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; PATIENT SATISFACTION; PRURITUS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VERRUCA VULGARIS; INTRADERMAL DRUG ADMINISTRATION; WARTS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; WARTS;

EID: 84918810822     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-014-0093-5     Document Type: Review

References (46)

1. Bolognia JL, Jorizzo JL, Schaffer JV. Human papillomaviruses. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012 (Print).
2. Bruggink SC, de Koning MN, Gussekloo J, et al. Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics. J Clin Virol. 2012;55(3):250–5.
3. Kilkenny M, Merlin K, Yunng R, Marks R. The prevalence of common skin conditions in Australian school students: 1. Common, plane and plantar viral warts. Br J Dermatol. 1998;138:8411–5.
4. Spira R, Mignard M, Doutre MS, et al. Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d’Epidémiologie Clinique du SIDA en Aquitaine. Arch Dermatol. 1998;134(10):1208–12.
5. Wilmer EN, Gustafson CJ, Ahn CS, et al. Most common dermatologic problems identified by dermatologists and non-dermatologists, 2001–2010. Cutis (in press).
6. Fox PA, Tung MY. Human papillomavirus: burden of illness and treatment cost considerations. Am J Clin Dermatol. 2005;6(6):365–81.
7. Dall’oglio F, D’Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2012;13(2):73–96.
8. Fields K, Milikowski C, Jewell T, Fields J. Localized diffuse melanosis associated with melanoma successfully treated with imiquimod cream 5 %: a case report and review of the literature. Cutis. 2014;93(3):145–50.
9. Luyten A, Sörgel P, Clad A, et al. Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy Network. J Am Acad Dermatol. 2014;70(4):644–50.
10. Salasche S, Shumack S. A review of imiquimod 5 % cream for the treatment of various dermatological conditions. Clin Exp Dermatol. 2003;28(Suppl 1):1–3.
11. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5 % imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134(1):25–30.
12. Reeder VJ, Gustafson CJ, Davis SA, et al. The treatment and demographics of warts: an analysis of national trends. J Drugs Dermatol. 2013;12(12):1411–5.
13. Oxford Centre for Evidence-based Medicine—Levels of Evidence. University of Oxford, Medical Sciences Division. March 2009. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed 18 June 2014.
14. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5 % imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol. 2000;143(5):1026–31.
15. Grussendorf-Conen EI, Jacobs S. Efficacy of imiquimod 5 % cream in the treatment of recalcitrant warts in children. Pediatr Dermatol. 2002;19(3):263–6.
16. Grussendorf-Conen EI, Jacobs S, Rübben A, Dethlefsen U. Topical 5 % imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities. Dermatology. 2002;205(2):139–45.
17. Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5 % cream. Eur J Dermatol. 2002;12(4):347–9.
18. Housman TS, Jorizzo JL. Anecdotal reports of 3 cases illustrating a spectrum of resistant common warts treated with cryotherapy followed by topical imiquimod and salicylic acid. J Am Acad Dermatol. 2002;47(4 Suppl):S217–20.
19. Atzori L, Pinna AL, Ferreli C. Extensive and recalcitrant verrucae vulgares of the great toe treated with imiquimod 5 % cream. J Eur Acad Dermatol Venereol. 2003;17(3):366–7.
20. Kim MB, Ko HC, Jang HS, et al. Treatment of flat warts with 5 % imiquimod cream. J Eur Acad Dermatol Venereol. 2006;20(10):1349–50.
21. Oster-Schmidt C. Imiquimod: a new possibility for treatment-resistant verrucae planae. Arch Dermatol. 2001;137(5):666–7.
22. Schwab RA, Elston DM. Topical imiquimod for recalcitrant facial flat warts. Cutis. 2000;65(3):160–2.
23. Khan Durani B, Jappe U. Successful treatment of facial plane warts with imiquimod. Br J Dermatol. 2002;147(5):1018.
24. Leong CM, Tarbotton J, Hibma M. Self-applied treatment of persistent plantar wart with 5 % imiquimod cream. N Z Med J. 2007;120(1259):U2668.
25. Sparling JD, Checketts SR, Chapman MS. Imiquimod for plantar and periungual warts. Cutis. 2001;68(6):397–9.
26. Tucker SB, Ali A, Ransdell BL. Plantar wart treatment with combination imiquimod and salicylic acid pads. J Drugs Dermatol. 2003;2(2):124–6.
27. Yesudian PD, Parslew RA. Treatment of recalcitrant plantar warts with imiquimod. J Dermatol Treat. 2002;13(1):31–3.
28. Zamiri M, Gupta G. Plantar warts treated with an immune response modifier: a report of two cases. Clin Exp Dermatol. 2003;28(Suppl 1):45–7.
29. Micali G, Dall’Oglio F, Nasca MR. An open label evaluation of the efficacy of imiquimod 5 % cream in the treatment of recalcitrant subungual and periungual cutaneous warts. J Dermatol Treat. 2003;14(4):233–6.
30. Poochareon V, Berman B, Villa A. Successful treatment of butcher’s warts with imiquimod 5 % cream. Clin Exp Dermatol. 2003;28(Suppl 1):42–4.
31. Harwood CA, Perrett CM, Brown VL, et al. Imiquimod cream 5 % for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol. 2005;152(1):122–9.
32. Ben M’barek L, Mebazaa A, Euvrard S, et al. 5 % topical imiquimod tolerance in transplant recipients. Dermatology. 2007;215(2):130–3.
33. Weisshaar E, Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol. 2000;80(4):306–7.
34. Hagman JH, Bianchi L, Marulli GC, Soda R, Chimenti S. Successful treatment of multiple filiform facial warts with imiquimod 5 % cream in a patient infected by human immunodeficiency virus. Clin Exp Dermatol. 2003;28(3):260–1.
35. Cutler K, Kagen MH, Don PC, et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus. Acta Derm Venereol. 2000;80(2):134–5.
36. Juschka U, Hartmann M. Topical treatment of common warts in an HIV-positive patient with imiquimod 5 % cream. Clin Exp Dermatol. 2003;28(Suppl 1):48–50.
37. Am Massing. Epstein WL. Natural history of warts. Arch Dermatol. 1963;87:306–10.
38. Plasencia JM. Cutaneous warts: diagnosis and treatment. Prim Care. 2000;27:423–34.
39. Bunney MH, Nolan MW, Williams DA. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol. 1976;94:667–79.
40. Miller DM, Brodell RT. Human papillomavirus infection: treatment options for warts. Am Fam Physician. 1996;53:135–50.
41. Bolton RA. Non-genital warts: classification and treatment options. Am Fam Physician. 1991;43:2049–56.
42. Kenton-Smith J, Tan ST. Pulsed dye laser therapy for viral warts. Br J Plast Surg. 1999;52:554–8.
43. Sloan K, Haberman H, Lynde CW. Carbon dioxide laser-treatment of resistant verrucae vulgaris: retrospective analysis. J Cutan Med Surg. 1998;2:142–5.
44. Jacobsen E, McGraw R, McCagh S. Pulsed dye laser efficacy as initial therapy for warts and against recalcitrant verrucae. Cutis. 1997;59:206–8.
45. Langley PC. A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. J Med Econ. 2010;13(1):1–7.
46. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care. 1999;5(1):69–77.